Growth and survival of renal failure rats that received oral microencapsulated genetically engineered E. coli DH5 cells for urea removal.
In our earlier reports we have introduced a new method for urea removal in renal failure. This is based on the oral administration of polymeric artificial cells containing nonpathogenic genetically engineered E. coli DH5 cells to renal failure rats. This resulted in the lowering of systemic uremic urea level to normal range without elevation of ammonia. The present article deals with the safety study of this approach. Microscopic study follows changes in microcapsule morphology with time are described. Two parameters, the body weight of the renal failure rats and, the survival for of the renal failure rats receiving microcapsules containing genetically engineered E. coli DH5 cells are discussed in this article. Result shows that there is no significant difference between the weight profile of uremic rats receiving oral therapy and normal control rats. Also the treated group of uremic rats survived longer than the untreated uremic rats.
Prakash
S
S
Artificial Cells and Organs Research Centre Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Chang
T M
TM
D000284:Administration, Oral; D000818:Animals; D001835:Body Weight; D018572:Disease-Free Survival; D004339:Drug Compounding / Q000379:methods*; D004926:Escherichia coli / Q000235:genetics*; D005818:Genetic Engineering; D051381:Rats; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000628:therapy*; D017582:Renal Replacement Therapy / Q000379:methods; D014508:Urea / Q000493:pharmacokinetics*
D014508:Urea